Back to Search Start Over

Elevated Glucose Levels Favor Sars-Cov-2 Infection and Monocyte Response Through a Hif-1α/Glycolysis Dependent Axis

Authors :
Raisa G. Ulaf
Pedro Vieira
Pierina Lorencini Parise
Helison Rafael Pereira do Carmo
Victor Corasolla Carregari
Lais D. Coimbra
Fabricio Pereira
Helder I. Nakaya
Fernanda Crunfli
Licio A. Velloso
A. F. Bernardes
Gustavo Gastão Davanzo
Jeffersson Leandro Jimenez Restrepo
Alexandre Borin
Vinícius O. Boldrini
Daniel Martins-de-Souza
Carlos Alberto Oliveira de Biagi
José Luiz Proença Modena
André Damasio
Maria Luiza Moretti
Marcus V. Agrela
Marcelo A. Mori
Andre C. Palma
Stéfanie Primon Muraro
Lauar de Brito Monteiro
Guilherme Reis-de-Oliveira
M. C. Martini
Andrei C. Sposito
Daniel Teixeira
Natalia S Brunetti
Robson Francisco Carvalho
Thyago A. Nunes
Pedro Henrique Vendramini
Alessandro S. Farias
Karina Rodrigues Santos
Marco Aurélio Ramirez Vinolo
André Schwambach Vieira
Ana Campos Codo
Gabriela F. P. de Souza
Eli Mansour
Source :
SSRN Electronic Journal.
Publication Year :
2020
Publisher :
Elsevier BV, 2020.

Abstract

COVID-19 can result in severe lung injury. It remained to be determined why diabetic individuals with uncontrolled glucose levels are more prone to develop the severe form of COVID-19. The molecular mechanism underlying SARS-CoV-2 infection and what determines the onset of the cytokine storm found in severe COVID-19 patients are unknown. Monocytes/macrophages are the most enriched immune cell types in the lungs of COVID-19 patients and appear to have a central role in the pathogenicity of the disease. These cells adapt their metabolism upon infection and become highly glycolytic, which facilitates SARS-CoV-2 replication. The infection triggers mitochondrial ROS production, which induces stabilization of hypoxia-inducible factor- 1α (HIF - 1α) and consequently promotes glycolysis. HIF- 1α-induced changes in monocyte metabolism by SARS-CoV-2 infection directly inhibit T cell response and reduce epithelial cell survival. Targeting HIF-1 ɑ may have great therapeutic potential for the development of novel drugs to treat COVID-19.

Details

ISSN :
15565068
Database :
OpenAIRE
Journal :
SSRN Electronic Journal
Accession number :
edsair.doi...........5c326e447820956835055567ddd1e6c1
Full Text :
https://doi.org/10.2139/ssrn.3606770